Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors

M Lange, F Joly, J Vardy, T Ahles, M Dubois, L Tron, G Winocur, M B De Ruiter, H Castel, M Lange, F Joly, J Vardy, T Ahles, M Dubois, L Tron, G Winocur, M B De Ruiter, H Castel

Abstract

Background: Advances in diagnostic and therapeutic strategies in oncology have significantly increased the chance of survival of cancer patients, even those with metastatic disease. However, cancer-related cognitive impairment (CRCI) is frequently reported in patients treated for non-central nervous system cancers, particularly during and after chemotherapy.

Design: This review provides an update of the state of the art based on PubMed searches between 2012 and March 2019 on 'cognition', 'cancer', 'antineoplastic agents' or 'chemotherapy'. It includes the most recent clinical, imaging and pre-clinical data and reports management strategies of CRCI.

Results: Evidence obtained primarily from studies on breast cancer patients highlight memory, processing speed, attention and executive functions as the most cognitive domains impaired post-chemotherapy. Recent investigations established that other cancer treatments, such as hormone therapies and targeted therapies, can also induce cognitive deficits. Knowledge regarding predisposing factors, biological markers or brain functions associated with CRCI has improved. Factors such as age and genetic polymorphisms of apolipoprotein E, catechol-O-methyltransferase and BDNF may predispose individuals to a higher risk of cognitive impairment. Poor performance on neuropsychological tests were associated with volume reduction in grey matter, less connectivity and activation after chemotherapy. In animals, hippocampus-based memory and executive functions, mediated by the frontal lobes, were shown to be particularly susceptible to the effects of chemotherapy. It involves altered neurogenesis, mitochondrial dysfunction or brain cytokine response. An important next step is to identify strategies for managing cognitive difficulties, with primary studies to assess cognitive training and physical exercise regimens.

Conclusions: CRCI is not limited to chemotherapy. A multidisciplinary approach has improved our knowledge of the complex mechanisms involved. Nowadays, studies evaluating cognitive rehabilitation programmes are encouraged to help patients cope with cognitive difficulties and improve quality of life during and after cancer.

Keywords: managementof cognitive impairment; animal model; cancer patients; cancer treatments; cancer-related cognitive impairment; neuro-imaging.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Figures

Figure 1
Figure 1
Schema outlining the complexity of cancer-related cognitive impairment. In cancer patients and survivors, the effect of chemotherapy on cognitive functions has been shown to impact different brain areas involved in attention, processing speed, memory, and executive functions. Recently, newly developed therapies involving targeted therapy, hormone therapy, and immunotherapy also appear to affect cognitive functions. The cancer treatments were associated with changes in brain volume, metabolic, or network modifications potentially related to direct neuronal toxicity and inflammation and genetic polymorphism combined with the aging process, patients’ emotional status, co-morbidities, or lifestyle. Cancer patients can be affected in multiple aspects, highlighting the urgency of initiating specific onco-neuro-psychological patient care. APOE, Apolipoprotein E; BBB, blood-brain barrier; BDNF, brain-derived neurotrophic factor; Cho, choline; COMT, catechol-O-methyltransferase; IL1-R1, interleukin-1-receptor1; Myo-I, Myo-inositol; NAA, N-acetylaspartate; pNF-H, phosphorylated neurofilament subunit H; TNF-α, tumour necrosis factor-alpha; sTNF-RII, tumour necrosis factor-receptor type II.
Figure 2
Figure 2
Brain regions that show changes in brain morphology, perfusion and/or activation after chemotherapy as reported by longitudinal studies issued from Li & Caeyenberghs, 2018 [11]. Changes in morphology [voxel-based morphometry (VBM) of grey matter or diffusion tensor imaging of white matter] are indicated in red. Changes in perfusion [arterial spin labelling (ASL)] are indicated in green. Changes in brain activation (fMRI) are indicated in blue. Several brain regions reveal overlap between modalities: magenta for overlap between brain morphology and activation, cyan for overlap between activation and perfusion, yellow for overlap between morphology and perfusion, orange for overlap between the three modalities. White matter regions are not included in the figure, nor was the cerebellum. However, two fMRI studies have revealed changes in the right cerebellum (lobule 4–5 and Crus- 2). The longitudinal studies are including cancer types, sample sizes, and chemotherapeutic agents: morphological changes—VBM: [10] 22 TC+, 43 TC−, 25 HC; bleomycin, etoposide, and cisplatin; [91] 8 BC+, 6 BC−; doxorubicin and cyclophosphamide/fluorouracil, epirubicin, cyclophosphamide, with or without docetaxel. In two patients, trastuzumab was also administered; [92] 14 GC+, 11 HC; capecitabine, oxaliplatin; [93] 19 BC+, 19 HC; fluorouracil, epirubicin, cyclophosphamide, docetaxel/cyclophosphamide, docetaxel/cyclophosphamide, doxorubicin; [94] 16 BC+, 12 BC−, 15 HC; doxorubicin/cyclophosphamide/paclitaxel, docetaxel/cyclophosphamide, docetaxel/carboplatin, docetaxel/doxorubicin/cyclophosphamide, docetaxel/cisplatin, paclitaxel. DTI: [95] 22 TC+, 43 TC−, 25 HC; bleomycin, etoposide, and cisplatin; [96] 34 BC+, 16 BC−, 19 HC; fluorouracil, epirubicin, and cyclophosphamide with or without paclitaxel; [97] 26 BC+, 23 BC−, 30 NC; doxorubicin, cyclophosphamide with or without docetaxel or paclitaxel, fluorouracil, epirubicin, cyclophophamide. Changes in perfusion: [98] 31 BC+, 34 HC; doxorubicin, cyclophosphamide, docetaxel; [99] 27 BC+, 26 BC−, 26 HC; doxorubicin, cyclophosphamide, paclitaxel/docetaxel, cyclophosphamide//docetaxel, doxorubicin, cyclophosphamide/docetaxel, cisplatin/doxorubicin, cyclophosphamide/paclitaxel. Changes in activation: [100] 18 BC+, 12 HC; doxorubicin, cyclophosphamide with or without docetaxel. One patient also received trastuzumab; [101] 18 BC+, 16 BC−, 18 HC; fluorouracil, epirubicin, cyclophophamide, with or without paclitaxel; [92] 14 GC+, 11 HC; capecitabine, oxaliplatin; [102] 21 BC+, 21 HC, fluororacil, epirubicin, cyclophosphamide, docetaxel/cyclophosphamide, docetaxel/cyclophosphamide, doxorubicin; [103] 16 BC+, 12 BC−, 15 HC; doxorubicin/cyclophosphamide/paclitaxel/docetaxel/doxorubicin, cyclophosphamide/doxorubicin/cyclophosphamide [20] 28 BC+, 24 BC−, 31 HC; doxorubicin, cyclophosphamide with or without docetaxel or paclitaxel/fluorouracil, epirubicin, cyclophophamide. BC, breast cancer; TC, testicular cancer; GC, gastric cancer; HC, healthy controls. Reprinted from [11], Copyright (2019), with permission from Elsevier.

References

    1. Joly F., Giffard B., Rigal O. Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force Symposium and update since 2012. J Pain Symptom Manage. 2015;50(6):830–841.
    1. Ahles T.A., Root J.C., Ryan E.L. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30(30):3675–3686.
    1. Deprez S., Kesler S.R., Saykin A.J. International cognition and cancer task force recommendations for neuroimaging methods in the study of cognitive impairment in non-CNS cancer patients. J Natl Cancer Inst. 2018;110(3):223–231.
    1. Wefel J.S., Vardy J., Ahles T., Schagen S.B. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–708.
    1. Lange M., Licaj I., Clarisse B. Cognitive complaints in cancer survivors and expectations for support: results from a web-based survey. Cancer Med. 2019;8(5):2654–2663.
    1. Ganz P.A., Kwan L., Castellon S.A. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105(11):791–801.
    1. Joly F., Heutte N., Duclos B. Prospective evaluation of the impact of antiangiogenic treatment on cognitive functions in metastatic renal cancer. Eur Urol Focus. 2016;15:642–649.
    1. Joly F., Castel H., Tron L. Potential impact of immunotherapy agents on cognitive function in cancer patients. JNCI. 2019
    1. Winocur G., Johnston I., Castel H. Chemotherapy and cognition: international cognition and cancer task force recommendations for harmonising preclinical research. Cancer Treat Rev. 2018;69:72–83.
    1. Amidi A., Agerbæk M., Wu L.M. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav. 2017;11(3):769–783.
    1. Li M., Caeyenberghs K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci Biobehav Rev. 2018;92:304–317.
    1. Ingraham L.G., Aiken C.B. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10(1):120–124.
    1. Cheung Y.T., Foo Y.L., Shwe M. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014;67(7):811–820.
    1. Bell M.L., Dhillon H.M., Bray V.J., Vardy J.L. Important differences and meaningful changes for the Functional Assessment of Cancer Therapy-Cognitive Function (FACTCog) J Patient Rep Outcomes. 2018;2(1):1–11.
    1. Dhillon H.M., Tannock I.F., Pond G.R. Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. J Cancer Surviv. 2018;12(2):178–185.
    1. Pullens M.J., De V.J., Van Warmerdam L.J. Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology. 2013;22(8):1783–1789.
    1. Ng T., Dorajoo S.R., Cheung Y.T. Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian Breast Cancer Survivors. Psychooncology. 2018;27(4):1185–1192.
    1. Bray V.J., Dhillon H.M., Vardy J.L. Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv. 2018;12(4):537–559.
    1. Apple A.C., Schroeder M.P., Ryals A.J. Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. Neuroimage Clin. 2018;20:110–118.
    1. Menning S., de Ruiter M.B., Veltman D.J. Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS One. 2017;12(3):e0171724.
    1. Lindner O.C., Phillips B., McCabe M.G. A meta-analysis of cognitive impairment following adult cancer chemotherapy. Neuropsychology. 2014;28(5):726–740.
    1. Hodgson K.D., Hutchinson A.D., Wilson C.J., Nettelbeck T. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013;39(3):297–304.
    1. Collins B., Mackenzie J., Tasca G.A. Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy. J Int Neuropsychol Soc. 2014;20(4):370–379.
    1. Vardy J.L., Dhillon H.M., Pond G.R. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33(34):4085–4092.
    1. Wouters H., Baars J.W., Schagen S.B. Neurocognitive function of lymphoma patients after treatment with chemotherapy. Acta Oncol. 2016;55(9-10):1121–1125.
    1. Hess L.M., Huang H.Q., Hanlon A.L. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;139(3):541–545.
    1. Ganz P.A., Petersen L., Castellon S.A. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol. 2014;32(31):3559–3567.
    1. Amidi A., Christensen S., Mehlsen M. Long-term subjective cognitive functioning following adjuvant systemic treatment: 7-9 years follow-up of a nationwide cohort of women treated for primary breast cancer. Br J Cancer. 2015;113(5):794–801.
    1. Janelsins M.C., Heckler C.E., Peppone L.J. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017;35(5):506–514.
    1. Galica J., Rajacich D., Kane D., Pond G.R. The impact of chemotherapy-induced cognitive impairment on the psychosocial adjustment of patients with nonmetastatic colorectal cancer. Clin J Oncol Nurs. 2012;16(2):163–169.
    1. Pereira S., Fontes F., Sonin T. Neurological complications of breast cancer: a prospective cohort study. Breast. 2015;24(5):582–587.
    1. Dubois M., Lapinte N., Villier V. Chemotherapy-induced long-term alteration of executive functions and hippocampal cell proliferation: role of glucose as adjuvant. Neuropharmacology. 2014;79:234–248.
    1. Fardell J.E., Vardy J., Johnston I.N. The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory. Life Sci. 2013;93(17):596–604.
    1. Winocur G., Henkelman M., Wojtowicz J.M. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res. 2012;18(11):3112–3121.
    1. Fardell J.E., Vardy J., Monds L.A., Johnston I.N. The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy. Behav Brain Res. 2015;291:80–88.
    1. Fardell J.E., Zhang J., De S.R. The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. Psychopharmacology (Berl) 2014;231(5):841–852.
    1. Seigers R., Loos M., Van T.O. Neurobiological changes by cytotoxic agents in mice. Behav Brain Res. 2016;299:19–26.
    1. Lim I., Joung H.Y., Yu A.R. PET evidence of the effect of donepezil on cognitive performance in an animal model of chemobrain. Biomed Res Int. 2016;2016:1.
    1. Christie L.A., Acharya M.M., Parihar V.K. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res. 2012;18(7):1954–1965.
    1. Lomeli N., Di K., Czerniawski J. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 2017;102:274–286.
    1. Pomykala K.L., Ganz P.A., Bower J.E. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav. 2013;7(4):511–523.
    1. Lyon D.E., Cohen R., Chen H. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J Neuroimmunol. 2016;301:74–82.
    1. Schilder C.M., Seynaeve C., Linn S.C. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psychooncology. 2012;21(5):479–487.
    1. Danhauer S.C., Legault C., Bandos H. Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2013;20(5):532–552.
    1. Bender C.M., Merriman J.D., Gentry A.L. Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015;121(15):2627–2636.
    1. Le Rhun E., Delbeuck X., Lefeuvre-Plesse C. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Res Treat. 2015;152(3):569–580.
    1. Phillips K.A., Regan M.M., Ribi K. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016;114(9):956–964.
    1. Van D.y., Crespi C.M., Bower J.E. The cognitive effects of endocrine therapy in survivors of breast cancer: a prospective longitudinal study up to 6 years after treatment. Cancer. 2019;125:681–689.
    1. Wiechno P.J., Sadowska M., Kalinowski T. Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life? Psychooncology. 2013;22(2):346–351.
    1. Gonzalez B.D., Jim H.S., Booth-Jones M. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021–2027.
    1. Morote J., Tabernero A.J., Alvarez Ossorio J.L. Cognitive function in patients with prostate cancer receiving luteinizing hormone-releasing hormone analogues: a prospective, observational, multicenter study. Int J Radiat Oncol Biol Phys. 2017;98(3):590–594.
    1. Thiery-Vuillemin A., Poulsen M.H., Lagneau E. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study. ESMO Open. 2018;3(5):e000397.
    1. McGinty H.L., Phillips K.M., Jim H.S. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271–2280.
    1. Dubois M., Le J.V., Tonon M.C. Evaluation of the impact of the cancer therapy everolimus on the central nervous system in mice. PLoS One. 2014;9(12):e113533.
    1. McGinnis G.J., Friedman D., Young K.H. Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget. 2017;8(6):9155–9173.
    1. Ramalho M., Fontes F., Ruano L. Cognitive impairment in the first year after breast cancer diagnosis: a prospective cohort study. Breast. 2017;32:173–178.
    1. Vardy J.L., Stouten-Kemperman M.M., Pond G. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav. 2019;13(1):15–26.
    1. Li J., Yu L., Long Z. Perceived cognitive impairment in Chinese patients with breast cancer and its relationship with post-traumatic stress disorder symptoms and fatigue. Psychooncology. 2015;24(6):676–682.
    1. Cheung Y.T., Shwe M., Chui W.K. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. Ann Pharmacother. 2012;46(12):1645–1655.
    1. Seliktar N., Polek C., Brooks A., Hardie T. Cognition in breast cancer survivors: hormones versus depression. Psychooncology. 2015;24(4):402–407.
    1. Libert Y., Borghgraef C., Beguin Y. Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: a longitudinal cohort study. Psychooncology. 2017;26(12):2086–2093.
    1. Menning S., de Ruiter M.B., Kieffer J.M. Cognitive impairment in a subset of breast cancer patients after systemic therapy-results from a longitudinal study. J Pain Symptom Manage. 2016;52(4):560–569.
    1. Kesler S.R., Rao V., Ray W.J., Rao A. Probability of Alzheimer's disease in breast cancer survivors based on gray-matter structural network efficiency. Alzheimers Dement (Amst) 2017;9:67–75.
    1. Schagen S.B., Das E., Vermeulen I. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology. 2012;21(10):1132–1135.
    1. Jacobs W., Das E., Schagen S.B. Increased cognitive problem reporting after information about chemotherapy-induced cognitive decline: the moderating role of stigma consciousness. Psychol Health. 2017;32(1):78–93.
    1. Morin R.T., Midlarsky E. Treatment with chemotherapy and cognitive functioning in older adult cancer survivors. Arch Phys Med Rehabil. 2018;99(2):257–263.
    1. Chen B.T., Jin T., Patel S.K. Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat. 2018;172(2):363–370.
    1. Rambeau A., Beauplet B., Laviec H. Prospective comparison of the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Examination (MMSE) in geriatric oncology. J Geriatr Oncol. 2019;10(2):235–240.
    1. Mandelblatt J.S., Small B.J., Luta G. Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. J Clin Oncol. 2018 doi:JCO1800140.
    1. Mandelblatt J.S., Clapp J.D., Luta G. Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance) Cancer. 2016;122(22):3555–3563.
    1. Lange M., Heutte N., Noal S. Cognitive changes after adjuvant treatment in older adults with early-stage breast cancer. Oncologist. 2019;24(1):62–68.
    1. Lange M., Heutte N., Rigal O. Decline in cognitive function in older adults with early-stage breast cancer after adjuvant treatment. Oncologist. 2016;21(11):1337–1348.
    1. Anstey K.J., Sargent-Cox K., Cherbuin N., Sachdev P.S. Self-reported history of chemotherapy and cognitive decline in adults aged 60 and older: the PATH through life project. Gerona. 2015;70(6):729–735.
    1. Okereke O.I., Meadows M.E. More evidence of an inverse association between cancer and alzheimer disease. JAMA Netw Open. 2019;2(6):e196167..
    1. Cherrier M.M., Higano C.S. Impact of androgen deprivation therapy on mood, cognition, and risk for AD. Urol Oncol. 2019
    1. Shaffer V.A., Merkle E.C., Fagerlin A. Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: findings from a prospective cohort study. Med Care. 2012;50(10):849–855.
    1. Carroll J.E., Van D.K., Bower J.E. Cognitive performance in survivors of breast cancer and markers of biological aging. Cancer. 2019;125(2):298–306.
    1. Ahles T.A., Li Y., McDonald B.C. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. Psychooncology. 2014;23(12):1382–1390.
    1. van der Willik K.D., Koppelmans V., Hauptmann M. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. Breast Cancer Res. 2018;20(1):135.
    1. Cheung Y.T., Ng T., Shwe M. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol. 2015;26(7):1446–1451.
    1. Williams A.M., Shah R., Shayne M. Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol. 2018;314:17–23.
    1. Chae J.W., Ng T., Yeo H.L. Impact of TNF-alpha (rs1800629) and IL-6 (rs1800795) polymorphisms on cognitive impairment in Asian breast cancer patients. PLoS One. 2016;11(10):e0164204.
    1. Andreano J.M., Waisman J., Donley L., Cahill L. Effects of breast cancer treatment on the hormonal and cognitive consequences of acute stress. Psychooncology. 2012;21(10):1091–1098.
    1. Chae J.W., Chua P.S., Ng T. Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. Breast Cancer Res Treat. 2018;168(3):713–721.
    1. Kesler S.R., Watson C., Koovakkattu D. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav. 2013;7(4):501–510.
    1. Natori A., Ogata T., Sumitani M. Potential role of pNF-H, a biomarker of axonal damage in the central nervous system, as a predictive marker of chemotherapy-induced cognitive impairment. Clin Cancer Res. 2015;21(6):1348–1352.
    1. Merriman J.D., Aouizerat B.E., Cataldo J.K. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine. 2014;65(2):192–201.
    1. Koleck T.A., Bender C.M., Sereika S.M. Apolipoprotein E genotype and cognitive function in postmenopausal women with early-stage breast cancer. Oncol Nurs Forum. 2014;41(6):E313–E325.
    1. Cheng H., Li W., Gan C. The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res. 2016;8(11):5087–5097.
    1. Ng T., Teo S.M., Yeo H.L. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol. 2016;18(2):244–251.
    1. Jenkins V., Thwaites R., Cercignani M. A feasibility study exploring the role of pre-operative assessment when examining the mechanism of ‘chemo-brain’ in breast cancer patients. Springerplus. 2016;5(1):390..
    1. Kim H.G., Shin N.-Y., Bak Y. Altered intrinsic brain activity after chemotherapy in patients with gastric cancer: a preliminary study. Eur Radiol. 2017;27(7):2679–2688.
    1. Lepage C., Smith A.M., Moreau J. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus. 2014;3(1):444. doi:101186/2193-1801-3-444.
    1. McDonald B.C., Conroy S.K., Smith D.J. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–S125.
    1. Amidi A., Hosseini S.M.H., Leemans A. Changes in brain structural networks and cognitive functions in testicular cancer patients receiving cisplatin-based chemotherapy. J Natl Cancer Inst. 2017;109(12):9041–9044.
    1. Deprez S., Amant F., Smeets A. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274–281.
    1. Menning S., de Ruiter M.B., Veltman D.J. Changes in brain white matter integrity after systemic treatment for breast cancer: a prospective longitudinal study. Brain Imaging Behav. 2018;12(2):324–334.
    1. Chen X., He X., Tao L. The attention network changes in breast cancer patients receiving neoadjuvant chemotherapy: evidence from an arterial spin labeling perfusion study. Sci Rep. 2017;7:1–9.
    1. Nudelman K.N.H., Wang Y., McDonald B.C. Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One. 2014;9(5):e96713..
    1. Conroy S.K., McDonald B.C., Ahles T.A. Chemotherapy-induced amenorrhea: a prospective study of brain activation changes and neurocognitive correlates. Brain Imaging Behav. 2013;7(4):491–500.
    1. Deprez S., Vandenbulcke M., Peeters R. Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32(19):2031–2038.
    1. López Zunini R.A., Scherling C., Wallis N. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav. 2013;7(4):460–477.
    1. McDonald B.C., Conroy S.K., Ahles T.A. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012;30(20):2500–2508.
    1. Billiet T., Emsell L., Vandenbulcke M. Recovery from chemotherapy-induced white matter changes in young breast cancer survivors? Brain Imaging Behav. 2018;12(1):64–77.
    1. Koppelmans V., de Ruiter M.B., van der Lijn F. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat. 2012;132(3):1099–1106.
    1. Amidi A., Hosseini S.M.H., Leemans A. Changes in brain structural networks and cognitive functions in testicular cancer patients receiving cisplatin-based chemotherapy. J Natl Cancer Inst. 2017;109(12)
    1. Stouten-Kemperman M.M., de Ruiter M.B., Caan M.W. Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Hum Brain Mapp. 2015;36(11):4638–4647.
    1. Kesler S.R., Blayney D.W. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016;2(2):185–192.
    1. Stouten-Kemperman M.M., de Ruiter M.B., Koppelmans V. Neurotoxicity in breast cancer survivors >/=10 years post-treatment is dependent on treatment type. Brain Imaging Behav. 2015;9(2):275–284.
    1. Stouten-Kemperman M.M., de Ruiter M.B., Boogerd W. Very late treatment-related alterations in brain function of breast cancer survivors. J Int Neuropsychol Soc. 2015;21(1):50–61.
    1. Jung M.S., Zhang M., Askren M.K. Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis. Brain Imaging Behav. 2017;11(1):86–97.
    1. Bray V.J., Dhillon H.M., Bell M.L. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol. 2017;35(2):217–225.
    1. Iarkov A., Appunn D., Echeverria V. Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats. Cancer Chemother Pharmacol. 2016;78(5):1033–1039.
    1. Lawrence J.A., Griffin L., Balcueva E.P. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv. 2016;10(1):176–184.
    1. Lyons L., ElBeltagy M., Bennett G., Wigmore P. Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLoS One. 2012;7(1):e30010..
    1. Bedillion M.F., Ansell E.B., Thomas G.A. Cancer treatment effects on cognition and depression: the moderating role of physical activity. Breast. 2019;44:73–80.
    1. King S., Green H.J. Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial. Front Oncol. 2015;5:72.
    1. Janelsins M.C., Peppone L.J., Heckler C.E. YOCAS(c)(R) yoga reduces self-reported memory difficulty in cancer survivors in a nationwide randomized clinical trial: investigating relationships between memory and sleep. Integr Cancer Ther. 2016;15(3):263–271.
    1. Winocur G., Wojtowicz J.M., Huang J., Tannock I.F. Physical exercise prevents suppression of hippocampal neurogenesis and reduces cognitive impairment in chemotherapy-treated rats. Psychopharmacology (Berl) 2014;231(11):2311–2320.
    1. Ercoli L.M., Petersen L., Hunter A.M. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology. 2015;24(11):1360–1367.
    1. Von A.D., Carpenter J.S., Saykin A. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2012;135:799–809.
    1. Kesler S., Hadi Hosseini S.M., Heckler C. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer. 2013;13(4):299–306.
    1. Knobf M.T., Thompson A.S., Fennie K., Erdos D. The effect of a community-based exercise intervention on symptoms and quality of life. Cancer Nurs. 2014;37(2):E43–E50.
    1. Schmidt M.E., Wiskemann J., Armbrust P. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. Int J Cancer. 2015;137(2):471–480.
    1. Galiano-Castillo N., Arroyo-Morales M., Lozano-Lozano M. Effect of an Internet-based telehealth system on functional capacity and cognition in breast cancer survivors: a secondary analysis of a randomized controlled trial. Support Care Cancer. 2017;25(11):3551–3559.
    1. Hartman S.J., Nelson S.H., Myers E. Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: the memory & motion study. Cancer. 2018;124:192–202.
    1. Damholdt M.F., Mehlsen M., O'Toole M.S. Web-based cognitive training for breast cancer survivors with cognitive complaints-a randomized controlled trial. Psychooncology. 2016;25(11):1293–1300.
    1. Karschnia P., Parsons M.W., Dietrich J. Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol. 2019;20(2):e92–e102.
    1. Ahles T.A., Root J.C. Cognitive effects of cancer and cancer treatments. Annu Rev Clin Psychol. 2018;14(1):425–451.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться